Elite Pharmaceuticals, Inc.
ELTP
$0.40
-$0.021-4.99%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -215.64% | -135.85% | 345.29% | 464.57% | 115.43% |
| Total Depreciation and Amortization | 51.34% | 44.42% | 28.99% | 11.12% | 2.33% |
| Total Amortization of Deferred Charges | 200.00% | 0.00% | -66.67% | -- | -75.00% |
| Total Other Non-Cash Items | 182.70% | 87.49% | -11,798.97% | -7,081.51% | -307.98% |
| Change in Net Operating Assets | 233.79% | 229.65% | 303.09% | 406.67% | -140.20% |
| Cash from Operations | 336.59% | 884.07% | 117.44% | -198.08% | -219.77% |
| Capital Expenditure | -35.27% | -213.00% | 71.85% | 85.89% | 82.76% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -117.50% | -357.31% | 56.17% | 85.89% | 82.76% |
| Total Debt Issued | -100.00% | -100.00% | -100.00% | -72.30% | -73.27% |
| Total Debt Repaid | 91.39% | 92.64% | 93.74% | 94.81% | -2,775.20% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 88.02% | 89.84% | 87.92% | 98.49% | -162.10% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 120.70% | 109.33% | 93.95% | -1.41% | -213.64% |